Eli Lilly (LLY) – The pharmaceutical giant ignites new growth surge with weight-loss medications and significantly raises annual forecast!
Reading Time: 3 minutes
Eli Lilly delivers a quarter to marvel at: Revenue +56% to $19.8 billion, EPS at $8.55 far exceeds expectations. Mounjaro and Zepbound drive the boom, with the annual forecast significantly raised. With the oral candidate Foundayo and a robust pipeline, LLY positions itself as a heavyweight in the billion-dollar GLP-1 market. Quarterly figures exceed expectations – Mounjaro and Zepbound drive revenue to record levels The stock of Eli Lilly rises sharply following strong quarterly figures, benefiting mainly from the ongoing boom...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
